Quarterly results round-up: Alere and Qiagen slash guidance after challenging Q2
This article was originally published in Clinica
Diagnostics firm Alere has cut its full-year financial guidance to $2.50-2.60 per diluted share, after being hit by lower-than-expected revenues from its health management business. Sales in the unit were down to $135.6m in the second quarter, compared to $149.8m during the same period last year, due to problems including reduced state government spending levels, which the company expects to persist for the rest of the year. Alere had previously predicted earnings of around $2.75 per share.